000170120 001__ 170120 000170120 005__ 20260318155255.0 000170120 0247_ $$2doi$$a10.2196/46893 000170120 0248_ $$2sideral$$a148531 000170120 037__ $$aART-2023-148531 000170120 041__ $$aeng 000170120 100__ $$0(orcid)0000-0003-2832-2266$$aLabarta, José I.$$uUniversidad de Zaragoza 000170120 245__ $$aEvaluating the Usefulness and Ease of Use of a Next-Generation–Connected Drug Delivery Device for Growth Hormone Therapy: Qualitative Study of Health Care Professionals’ Perceptions 000170120 260__ $$c2023 000170120 5060_ $$aAccess copy available to the general public$$fUnrestricted 000170120 5203_ $$aBackground: Digital solutions targeting children’s health have become an increasingly important element in the provision of integrated health care. For the treatment of growth hormone deficiency (GHD), a unique connected device is available to facilitate the delivery of recombinant human growth hormone (r-hGH) by automating the daily injection process and collecting injection data such that accurate adherence information is available to health care professionals (HCPs), caregivers, and patients. The adoption of such digital solutions requires a good understanding of the perspectives of HCPs as key stakeholders because they leverage data collection and prescribe these solutions to their patients. Objective: This study aimed to evaluate the third generation of the easypod device (EP3) for the delivery of r-hGH treatment from the HCP perspective, with a focus on perceived usefulness and ease of use. Methods: A qualitative study was conducted, based on a participatory workshop conducted in Zaragoza, Spain, with 10 HCPs experienced in the management of pediatric GHD from 7 reference hospitals in Spain. Several activities were designed to promote discussion among participants about predefined topics based on the Technology Acceptance Model and the Unified Theory of Acceptance and Use of Technology to provide their perceptions about the new device. Results: Participants reported 2 key advantages of EP3 over previous easypod generations: the touch screen interface and the real-time data transmission functionality. All participants (10/10, 100%) agreed that the new device should be part of a digital health ecosystem that provides complementary functionalities including data analysis. Conclusions: This study explored the perceived value of the EP3 autoinjector device for the treatment of GHD by HCPs. HCPs rated the new capabilities of the device as having substantial improvements and concluded that it was highly recommendable for clinical practice. EP3 will enhance decision-making and allow for more personalized care of patients receiving r-hGH. 000170120 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es 000170120 592__ $$a0.777$$b2023 000170120 593__ $$aHuman Factors and Ergonomics$$c2023$$dQ2 000170120 593__ $$aHealth Informatics$$c2023$$dQ2 000170120 594__ $$a3.4$$b2023 000170120 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000170120 700__ $$aDimitri, Paul 000170120 700__ $$aKeiser, Matthew 000170120 700__ $$aKoledova, Ekaterina 000170120 700__ $$aRivera-Romero, Octavio 000170120 7102_ $$11011$$2670$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Pediatría 000170120 773__ $$g10 (2023), e46893 [15 pp.]$$tJMIR Human Factors$$x2292-9495 000170120 8564_ $$s1058570$$uhttps://zaguan.unizar.es/record/170120/files/texto_completo.pdf$$yVersión publicada 000170120 8564_ $$s2262602$$uhttps://zaguan.unizar.es/record/170120/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000170120 909CO $$ooai:zaguan.unizar.es:170120$$particulos$$pdriver 000170120 951__ $$a2026-03-18-13:52:43 000170120 980__ $$aARTICLE